University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Norah Terrault, M.P.H., M.D.

Liver specialist

Dr. Norah Terrault is a hepatologist or liver specialist who is recognized internationally for the treatment of viral hepatitis and liver transplantation. Her research includes the study of viral hepatitis and its progression and treatment, especially in liver transplant patients. Her research includes several clinical trials related to preventing and treating chronic hepatitis C and B. Her studies in this area have been presented to the American Association for the Study of Liver Diseases, the leading organization for research in liver disease.

Terrault completed medical training at the University of Alberta and specialty medical training in Internal Medicine and Gastroenterology at the University of Toronto, both in Canada. Her post-doctoral fellowship in hepatology and viral hepatitis was completed at the University of California, San Francisco while earning a concurrent master's degree in public health from the University of California at Berkeley. She joined the medical staff at UCSF Medical Center in 1997.

Clinics

Liver Disease and Liver Transplant
350 Parnassus Ave., Suite 300
San Francisco, CA 94143
Phone: (415) 353-2318
Fax: (415) 353-2407

Hours: Monday to Friday
8:30 a.m. – 4:30 p.m.

Pancreas Transplant Services
400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143
Phone: (415) 353-1551
Pre-Transplant Fax: (415) 353-8708
Post-Transplant Fax: (415) 353-4183

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Norah Terrault

Education

University of Alberta School of Medicine 1987

Residencies

University of Toronto Health Network, Internal Medicine 1991

Fellowships

University of Toronto Health Network, Gastroenterology 1993
UCSF Medical Center, Gastroenterology 1995

Selected Research and Publications

  1. Terrault N, Monto A, Stinchon MR, Rusie E, Moreo K. New Therapies, Evidence, and Guidance in Hepatitis C Management: Expert Practices and Insights from an Educational Symposium at the AMCP 27th Annual Meeting Expo. J Manag Care Spec Pharm. 2015 Sep; 21(9):S1-S17.
  2. Dirchwolf M, Dodge JL, Gralla J, Bambha KM, Nydam T, Hung KW, Rosen HR, Feng S, Terrault NA, Biggins SW. The corrected donor age for hepatitis C virus-infected liver transplant recipients. Liver Transpl. 2015 Aug; 21(8):1022-30.
  3. Verna EC, Saxena V, Burton JR, O'Leary JG, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS, Terrault NA. Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation. 2015 Aug; 99(8):1644-51.
  4. Saxena V, Nyberg L, Pauly M, Dasgupta A, Nyberg A, Piasecki B, Winston B, Redd J, Ready J, Terrault NA. Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis. Hepatology. 2015 Sep; 62(3):715-25.
  5. Terrault N. Difficult-to-cure populations with chronic hepatitis c: Vanishing in the direct-acting antiviral era? Hepatology. 2015 Jul; 62(1):4-7.
  6. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3):649-59.
  7. Campos-Varela I, Lai JC, Verna EC, O'Leary JG, Todd Stravitz R, Forman LM, Trotter JF, Brown RS, Terrault NA. Hepatitis C Genotype Influences Post-liver Transplant Outcomes. Transplantation. 2015 Apr; 99(4):835-40.
  8. Price JC, Terrault NA. Treatment of hepatitis C in liver transplant patients: Interferon out, direct antiviral combos in. Liver Transpl. 2015 Apr; 21(4):423-34.
  9. Saxena V, Terrault NA. Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander? Dig Dis Sci. 2015 Apr; 60(4):806-9.
  10. Stock PG, Terrault NA. Human immunodeficiency virus and liver transplantation: Hepatitis C is the last hurdle. Hepatology. 2015 May; 61(5):1747-54.
  11. Ho CK, Maselli JH, Terrault NA, Gonzales R. High Rate of Hospital Admissions Among Patients with Cirrhosis Seeking Care in US Emergency Departments. Dig Dis Sci. 2015 Jul; 60(7):2183-9.
  12. Campos-Varela I, Straley S, Agudelo EZ, Carlson L, Terrault NA. Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients. Liver Transpl. 2015 Feb; 21(2):272-4.
  13. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: Just the tip of the iceberg? Hepatology. 2015 Feb; 61(2):703-11.
  14. Lai JC, Covinsky KE, Hayssen H, Lizaola B, Dodge JL, Roberts JP, Terrault NA, Feng S. Clinician assessments of health status predict mortality in patients with end-stage liver disease awaiting liver transplantation. Liver Int. 2015 Jan 28.
  15. Goel A, Terrault N. Reply. Liver Transpl. 2015 Mar; 21(3):416.
  16. Lai JC, Shoback DM, Zipperstein J, Lizaola B, Tseng S, Terrault NA. Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C. Dig Dis Sci. 2015 Jan 7.
  17. Price JC, Terrault NA. Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective. Liver Int. 2015 Jan; 35(1):7-8.
  18. Flemming JA, Kim WR, Terrault NA. Reply to prediction of hepatocellular carcinoma: Using a complex risk model or assisting for smoking cessation? Cancer. 2015 Apr 1; 121(7):1150.
  19. Sarkar M, Watt KD, Terrault N, Berenguer M. Outcomes in liver transplantation: does sex matter? J Hepatol. 2015 Apr; 62(4):946-55.
  20. Tejada-Strop A, Drobeniuc J, Mixson-Hayden T, Forbi JC, Le NT, Li L, Mei J, Terrault N, Kamili S. Disparate detection outcomes for anti-HCV IgG and HCV RNA in dried blood spots. J Virol Methods. 2015 Feb; 212:66-70.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.